Publication Cover
Drying Technology
An International Journal
Volume 31, 2013 - Issue 3
221
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Optimization of Freeze-Drying Cycle for Tert-Butanol–Based Formulations of Ibuprofen

, , , &
Pages 308-313 | Published online: 28 Feb 2013
 

Abstract

We carried out the formulation set-up and thermodynamics as well as morphological characterization of two systems: an aqueous-based formulation and an organic-solvent-based formulation with tert-butanol (TBA) at eutectic composition (20% TBA + water 80% by mass) containing ibuprofen as the model pharmaceutical active component. The goal was to carry out the optimization of a soft freeze-drying cycle for heat-sensitive drugs. The organic-based ibuprofen formulation had a glass transition temperature significantly higher compared to that of the aqueous-based ibuprofen formulation, which allowed much higher sublimation temperatures for these systems in comparison with the pure water-based ibuprofen formulations. The morphological study of the frozen organic-based formulation showed unexpected behavior in comparison with previous literature data reported for water-based formulations. For the same freezing rates, the mean diameters of the solvent crystals of organic-based formulations were much larger than that of ice crystals of aqueous-based formulation, which led to a freeze-dried matrix of higher permeability. In contrast to what was observed with the aqueous-based formulations, the freezing rates, in the range of classical industrial values investigated, had no significant effect on the supercooling of the liquid ibuprofen formulations tested as well as on the nucleation temperatures and on the morphology of the organic solvent crystals. All these singular characteristics, with lower sublimation enthalpies and higher equilibrium vapor pressure values previously measured with the same formulations in our laboratory, explain the large reduction of sublimation times observed during the soft freeze-drying processes for heat-sensitive drugs with organic (TBA)-based formulations.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.